Collaboration to identify antibodies for cancer targets

Iontas and IGEM Therapeutics will work together to develop novel immunoglobulin E antibodoes

Iontas, a specialist in the discovery and optimisation of fully human antibodies, announced it will collaborate with IGEM Therapeutics (IGEM), an immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer.

John McCafferty, CEO at Iontas, commented: “This collaboration capitalises on the antibody discovery capabilities at Iontas, which enable the generation of high-quality therapeutic antibodies using phage-display or mammalian-display. We maintain a strong interest in developing novel therapeutic approaches and recognise IgE therapeutics as an important addition to the armoury of novel cancer therapies. We are delighted to have the opportunity to work with fellow innovators at IGEM on these two exciting projects.”

The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase I/IIa study. Iontas will utilise its proprietary antibody discovery technology to help IGEM identify novel IgE antibodies against two targets.

IgE antibodies have been shown to permeate tumour tissue more effectively, exhibit enhanced effector functions and stimulate significantly greater levels of cytotoxicity and phagocytosis than IgG antibodies.

Iontas will apply its proprietary antibody discovery libraries and technologies to identify specific, high affinity antibodies against two tumour associated targets. Functional screening of IgE formatted antibodies will be carried out to identify the most appropriate candidates for therapeutic development.

Tim Wilson, CEO at IGEM, commented: “Iontas was selected as our development partner of choice because of their extensive experience and track record in delivering therapeutic antibodies. The combination of the IGEM IgE platform and the discovery capability of Iontas will rapidly expand our portfolio of antibodies and help meet our ambitions to progress new leads into the clinic.”